Offer - Urjas Oil for just ₹ 1
Supime 1000/500 Injection is a commercial drug that is prescribed in the form of Injection. Supime 1000/500 Injection also has some secondary and off-label uses. These are listed below.
The right dosage of Supime 1000/500 Injection depends on the age, gender, and medical history of the patient. The condition it has been prescribed for, and the route of administration also determine the right dosage. Refer to the dosage section for a detailed discussion.
Some other side effects of Supime 1000/500 Injection have been listed ahead. Usually, these side effects of Supime 1000/500 Injection go away soon, and do not persist beyond the duration of the treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Supime 1000/500 Injection's effect is Safe during pregnancy and Safe for lactating mothers. Further, the section on Supime 1000/500 Injection related warnings talks about Supime 1000/500 Injection's effects on the liver, heart and kidney.
Supime 1000/500 Injection is not recommended if you suffer from certain medical conditions as it can have adverse effects. Kidney Disease, Kidney Disease, Jaundice are examples of such conditions. Some other conditions that can be affected by Supime 1000/500 Injection are listed in the contraindications section below.
Additionally, Supime 1000/500 Injection may also adversely react with other medicines. A complete list of these interactions is given below.
Along with the above-mentioned precautions, remember that taking Supime 1000/500 Injection is considered not safe while driving, and is not addictive.
Supime 1000/500 Injection is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Is the use of Supime 1000/500 Injection safe for pregnant women?
There are no side effects of Supime in pregnant women.
Is the use of Supime 1000/500 Injection safe during breastfeeding?
Supime does not show any harmful effects in lactating women.
What is the effect of Supime 1000/500 Injection on the Kidneys?
Supime rarely affects the kidneys.
What is the effect of Supime 1000/500 Injection on the Liver?
Supime is not harmful for the liver.
What is the effect of Supime 1000/500 Injection on the Heart?
You can take Supime without any fear of damage to the heart.
If you are suffering from any of the following diseases, you should not take Supime 1000/500 Injection unless your doctor advises you to do so -
Is this Supime 1000/500 Injection habit forming or addictive?
No, there is no any evidence that Supime 1000/500 Injection is addictive.
Interaction between Food and Supime 1000/500 Injection
Eating certain foods may increase the time it takes Supime 1000/500 Injection to have an effect. You should consult your doctor about it.
Interaction between Alcohol and Supime 1000/500 Injection
Due to lack of research, there is no information about the side effects of taking Supime 1000/500 Injection with alcohol.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 291-292
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 729
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Maxipime™ (Cefepime Hydrochloride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; UNASYN® (ampicillin sodium/sulbactam sodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 725
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 160-162
